In results from a late-stage trial released in August, Vidaza was shown to have increased the survival of patients with a high-risk type of MDS from 15 months to 24 months.
Novartis announced today the early termination of the ALTITUDE trial, which was testing the effect of the direct renin inhibitor aliskiren (Rasilez, Tekturna) in type 2 diabetics at highrisk for cardiovascular and renal events.
This program joins private and public partners together in encouraging lifestyle changes that can prevent or delay the onset of Type 2 diabetes among those who are at highrisk.
These people see the federal budget deficit, the huge debt burden and the risk of a stagflation-type environment of low growth and high inflation, and cannot understand how investors could be piling into bonds.